Piper Sandler Maintains Overweight Rating for VectivBio Holding: Here's What You Need To Know

Piper Sandler has decided to maintain its Overweight rating of VectivBio Holding VECT and raise its price target from $23.00 to $25.00.

Shares of VectivBio Holding are trading up 6.0% over the last 24 hours, at $9.54 per share.

A move to $25.00 would account for a 162.05% increase from the current share price.

About VectivBio Holding

VectivBio Holding AG is a clinical stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need. The product candidate is apraglutide, which is a next generation, long-acting synthetic peptide analog of glucagon-like peptide-2, or GLP-2, which is developed as a differentiated therapeutic for a range of rare GI diseases, with an initial focus on short bowel syndrome.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.